barchart.com
Crohn's Disease Market Across The 7MM To Witness Upsurge In Growth From USD 9 Billion In 2023
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
It also notes rising diagnoses and interest in biomarkers and new drug development that could change care over the next decade.
Adult patients with Crohn’s disease, people on biologic therapies, clinicians treating IBD, patient advocates tracking drug access and cost, and researchers/industry watching the development pipeline.
What To Know
This article summarizes a market research report (DelveInsight) projecting Crohn’s disease market growth in the 7MM (US, EU4, UK, Japan) from about USD 9 billion in 2023 through 2034 and lists current and pipeline therapies.
The report highlights approved drugs, recent FDA approvals/fast-track notes, market share data (adalimumab leading in 2023), epidemiology estimates (≈2 million diagnosed prevalent cases in 7MM in 2023), and drivers of growth such as new therapies, biomarkers, and rising prevalence. It is a commercial market/forecast piece rather than a clinical study.
It names many specific drugs and companies and notes pipeline candidates and regulatory milestones (e.g., OMVOH approval, AVB-114 Fast Track). The article does not provide clinical guidance or detailed trial results.
If you want the original market tables or company breakdowns, the full DelveInsight report is behind a download/purchase link referenced in the article.
This is a commercial market forecast summarizing DelveInsight’s paid report; it compiles approvals, company activity, and pipeline lists but does not present new clinical trial data. Market predictions depend on future approvals, uptake, pricing, and healthcare policies, so they do not imply immediate changes to clinical care.
